QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

NTNXTICKER

Nutanix, Inc.

BEARISH stock

Congress has disclosed 1 buy and 5 sells of NTNX (Nutanix, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

1
Buy
5
Sell
-4
Net
5
Active politicians
Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
12.07
no sector median
how it's calculated
P/E = price ÷ earnings per share
$67.21 ÷ $5.57 = 12.07
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
25.88
no sector median
how it's calculated
P/B = price ÷ book value per share
$67.21 ÷ $2.60 = 25.88
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
50.51
no sector median
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($18.2B − $0.8B net cash) ÷ $0.3B = $17.4B ÷ $0.3B = 50.51
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

6 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Rob Bresnahan House SELL ◆ insider convergence · moderate Joint · Joint Ownership LPL Account 2025-01-13 0 days 0.0% $1K–$15K
0.2% of NW
64.4 ↗ filing
Daniel Goldman House SELL Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K 2023-04-10 23 days — $1K–$15K
<0.1% of NW
75.9 ↗ filing
Donna Shalala House SELL Self 2019-06-24 6 days — $1K–$15K 86.8 ↗ filing
Alan Lowenthal House SELL Spouse 2019-05-28 15 days — $1K–$15K 52.4 ↗ filing
Nicholas Taylor House SELL Spouse 2019-03-25 0 days — $1K–$15K 75.9 ↗ filing
Alan Lowenthal House BUY Spouse 2019-03-21 26 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in NTNX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

1
Congress trades with insider convergence
0
…with insider divergence
77
Insider open-market trades

Of the congressional trades in NTNX, 1 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-10-12 Sivaraman Rukmini C-suite SELL 10b5-1 $13.4M ↗ EDGAR
2026-10-12 Sivaraman Rukmini C-suite SELL 10b5-1 $4.0M ↗ EDGAR
2026-10-09 Sheppard Teresa Gayle Director SELL 10b5-1 $206K ↗ EDGAR
2026-10-09 Sheppard Teresa Gayle Director SELL 10b5-1 $52K ↗ EDGAR
2026-10-07 RAMASWAMI RAJIV C-suite SELL 10b5-1 $5.6M ↗ EDGAR
2026-10-06 RAMASWAMI RAJIV C-suite SELL 10b5-1 $13.2M ↗ EDGAR
2026-10-06 RAMASWAMI RAJIV C-suite SELL 10b5-1 $10.7M ↗ EDGAR
2026-09-24 Maner Tarkan C-suite SELL $4.8M ↗ EDGAR
2026-09-17 Sivaraman Rukmini C-suite SELL 10b5-1 $2.7M ↗ EDGAR
2026-06-01 Maner Tarkan C-suite SELL $1.7M ↗ EDGAR
2026-05-29 Maner Tarkan C-suite SELL $974K ↗ EDGAR
2025-10-02 Sheppard Teresa Gayle Director SELL 10b5-1 $222K ↗ EDGAR
2025-10-02 Sheppard Teresa Gayle Director SELL 10b5-1 $46K ↗ EDGAR
2025-10-02 RAMASWAMI RAJIV C-suite SELL 10b5-1 $8.0M ↗ EDGAR
2025-10-02 RAMASWAMI RAJIV C-suite SELL 10b5-1 $3.0M ↗ EDGAR
2025-09-30 Martin Brian C-suite SELL 10b5-1 $784K ↗ EDGAR
2025-09-16 Sivaraman Rukmini C-suite SELL 10b5-1 $892K ↗ EDGAR
2025-06-26 RAMASWAMI RAJIV C-suite SELL 10b5-1 $144K ↗ EDGAR
2025-06-16 Sivaraman Rukmini C-suite SELL 10b5-1 $138K ↗ EDGAR
2025-06-16 Sivaraman Rukmini C-suite SELL 10b5-1 $15K ↗ EDGAR
2025-06-05 de Groen Max Pieter Director SELL $421.0M ↗ EDGAR
2025-06-05 Gambale Virginia Director SELL $546K ↗ EDGAR
2025-05-30 GOMO STEVEN J Director SELL $1.1M ↗ EDGAR
2025-05-13 RAMASWAMI RAJIV C-suite SELL 10b5-1 $4.8M ↗ EDGAR
2025-03-24 RAMASWAMI RAJIV C-suite SELL 10b5-1 $580K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-10-12 Sivaraman Rukmini C-suite 10b5-1 SELL $13.4M
◆ insider 2026-10-12 Sivaraman Rukmini C-suite 10b5-1 SELL $4.0M
◆ insider 2026-10-09 Sheppard Teresa Gayle Director 10b5-1 SELL $206K
◆ insider 2026-10-09 Sheppard Teresa Gayle Director 10b5-1 SELL $52K
◆ insider 2026-10-07 RAMASWAMI RAJIV C-suite 10b5-1 SELL $5.6M
◆ insider 2026-10-06 RAMASWAMI RAJIV C-suite 10b5-1 SELL $13.2M
◆ insider 2026-10-06 RAMASWAMI RAJIV C-suite 10b5-1 SELL $10.7M
◆ insider 2026-09-24 Maner Tarkan C-suite SELL $4.8M
◆ insider 2026-09-17 Sivaraman Rukmini C-suite 10b5-1 SELL $2.7M
◆ insider 2026-06-01 Maner Tarkan C-suite SELL $1.7M
◆ insider 2026-05-29 Maner Tarkan C-suite SELL $974K
◆ insider 2025-10-02 Sheppard Teresa Gayle Director 10b5-1 SELL $222K
◆ insider 2025-10-02 Sheppard Teresa Gayle Director 10b5-1 SELL $46K
◆ insider 2025-10-02 RAMASWAMI RAJIV C-suite 10b5-1 SELL $8.0M
◆ insider 2025-10-02 RAMASWAMI RAJIV C-suite 10b5-1 SELL $3.0M
◆ insider 2025-09-30 Martin Brian C-suite 10b5-1 SELL $784K
◆ insider 2025-09-16 Sivaraman Rukmini C-suite 10b5-1 SELL $892K
◆ insider 2025-06-26 RAMASWAMI RAJIV C-suite 10b5-1 SELL $144K
◆ insider 2025-06-16 Sivaraman Rukmini C-suite 10b5-1 SELL $138K
◆ insider 2025-06-16 Sivaraman Rukmini C-suite 10b5-1 SELL $15K
◆ insider 2025-06-05 de Groen Max Pieter Director SELL $421.0M
◆ insider 2025-06-05 Gambale Virginia Director SELL $546K
◆ insider 2025-05-30 GOMO STEVEN J Director SELL $1.1M
◆ insider 2025-05-13 RAMASWAMI RAJIV C-suite 10b5-1 SELL $4.8M

FAQ Common questions

How much has Congress traded NTNX?

1 disclosed buys and 5 sells of NTNX (Nutanix, Inc.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade NTNX?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.